接受阿片类替代治疗的丙型肝炎病毒感染患者在接受无干扰素方案治疗后患者报告结局改善
研究纳入索非布韦3期临床试验的8450例HCV感染者,其中4.8%(407例)接受阿片类替代治疗(OST)。基线时OST使用者PRO评分显著较低(P<.0001)。无干扰素无利巴韦林方案治疗期间几乎所有PRO改善,OST者改善更明显;含干扰素方案则PRO下降,OST者获得SVR-12后PRO亦无一致改善。
要点
- 基线时OST使用者PRO评分较非使用者低3.5至15.6分(0-100量表,P<.0001)。
- 含干扰素方案治疗期间PRO显著下降,无论是否使用OST。
- 无干扰素无利巴韦林方案治疗期间PRO改善,OST者改善更明显。
核心结论
- 接受无干扰素方案治疗可在治疗期间及SVR-12后改善PRO,无论OST状态如何。
- 接受OST的HCV感染者使用含干扰素方案未获得类似PRO改善,提示基于干扰素的治疗可能较不适合该脆弱人群。
研究设计与样本
- 纳入索非布韦3期临床试验的HCV感染者,共8450例,其中4.8%(407例)接受OST。
- 在治疗前、治疗期间及治疗后完成4种PRO量表:SF-36v2、FACIT-F、CLDQ-HCV和WPAI-HCV。
主要发现
- 基线时OST接受者PRO评分显著较低,较非OST者低3.5至15.6分(0-100量表,P<.0001)。
- 接受聚乙二醇干扰素、利巴韦林和索非布韦(IFN+RBV+SOF)者治疗结束时PRO显著下降,无论是否使用OST。
- 接受含利巴韦林无干扰素方案者PRO显著但较小幅度下降,OST组与非OST组相似。
- 接受无干扰素且无利巴韦林方案者治疗期间几乎所有PRO改善,OST接受者改善更明显。
- OST接受者使用无干扰素无利巴韦林方案获得SVR-12与PRO改善相关;使用IFN+RBV+SOF获得SVR-12后PRO无一致改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a paucity of patient-reported outcomes (PROs) data for people undergoing hepatitis C virus (HCV) treatment who are treated with opioid substitution therapy (OST) for addiction. METHODS: Patients enrolled in phase 3 clinical trials of sofosbuvir completed 4 PRO instruments-SF-36v2, FACIT-F, CLDQ-HCV, and WPAI-HCV-before, during, and after treatment. RESULTS: A total of 8450 HCV-infected subjects were included; 4.8% (407) were receiving OST. At baseline, OST recipients had significantly (P < .0001) lower PRO scores (by -3.5 to -15.6 on a 0-100 scale). By the end of treatment, subjects receiving pegylated interferon, ribavirin, and sofosbuvir (IFN+RBV+SOF) experienced significant decreases in PROs regardless of OST use. Subjects receiving IFN-free RBV-containing regimens had significant but smaller PRO decreases, again similar in the OST and non-OST groups. Finally, subjects treated with regimens free of both IFN and RBV (IFN/RBV-free) showed improvements in nearly all PROs during treatment, with improvements more pronounced in OST recipients. Achieving a sustained virological response for 12 consecutive weeks after treatment cessation (SVR-12) was associated with improvement of PROs in OST recipients treated with IFN/RBV-free regimens. In contrast, OST recipients who achieved SVR-12 with IFN+RBV+SOF did not have consistent PRO gains after the SVR-12. CONCLUSIONS: Receiving IFN-free regimens leads to PRO improvement during treatment and after the SVR-12, regardless of OST status. HCV-infected subjects receiving OST did not experience similar PRO improvements with IFN-containing therapy, suggesting that IFN-based therapy may be less suitable for this vulnerable population.
引用
- Stepanova M, Thompson A, Doyle J, et al. Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. J Infect Dis. 2018. PMID: 29293991. doi:10.1093/infdis/jix681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。